GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

GSK

1,407

-3.27%↓

INDV

1,132

+1.16%↑

Search

AstraZeneca PLC

Closed

SectorHealthcare

10,440 -1.75

Overview

Share price change

24h

Current

Min

10434

Max

10458

Key metrics

By Trading Economics

Income

1.3B

2.9B

Sales

-1.3B

14B

P/E

Sector Avg

28.071

39.564

Dividend yield

2.43

Profit margin

21.46

Employees

94,300

EBITDA

648M

5.1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+26.31% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.43%

2.40%

Next Earnings

29 Jul 2025

Next Dividend date

8 Sept 2025

Next Ex Dividend date

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-24B

158B

Previous open

10441.75

Previous close

10440

News Sentiment

By Acuity

63%

37%

319 / 376 Healthcare

AstraZeneca PLC Chart

Past performance is not a reliable indicator of future results.

Related News

12 May 2025, 09:36 UTC

Major Market Movers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 Apr 2025, 10:14 UTC

Earnings

Correction to AstraZeneca Update

29 Apr 2025, 09:15 UTC

Earnings

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 Apr 2025, 08:12 UTC

Earnings

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 Apr 2025, 06:32 UTC

Earnings

AstraZeneca Sales, Earnings Rise

9 Jul 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 Jul 2025, 09:17 UTC

Hot Stocks

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New -2-

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 May 2025, 06:09 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Completes Acquisition of EsoBiotec

12 May 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 May 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 May 2025, 15:20 UTC

Earnings

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 Apr 2025, 13:09 UTC

Market Talk
Earnings

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 Apr 2025, 08:04 UTC

Market Talk
Earnings

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 Apr 2025, 06:05 UTC

Earnings

AstraZeneca 1Q Core EPS $2.49

29 Apr 2025, 06:04 UTC

Earnings

AstraZeneca 1Q Net Pft $2.92B

29 Apr 2025, 06:02 UTC

Earnings

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca Backs 2025 View

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q EPS $1.87

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Rev $13.59B

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Oper Pft $3.67B

29 Apr 2025, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 Apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 Apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 Apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 Apr 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 Apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

Peer Comparison

Price change

AstraZeneca PLC Forecast

Price Target

By TipRanks

26.31% upside

12 Months Forecast

Average 13,199 GBX  26.31%

High 16,500 GBX

Low 10,900 GBX

Based on 16 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

12

Buy

4

Hold

0

Sell

Sentiment

By Acuity

319 / 376 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.